logo-loader
viewGenetic Technologies

Genetic Technologies heads to market

au_australiancash350_54f8d9611af02.jpg

Genetic Technologies (ASX:GTG, NASDAQ:GENE) is preparing to reveal details of a capital raising. The ASX has granted the company a trading halt to organise.

GTG is a molecular diagnostics company, with its lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

The halt will remain in place until the opening of trade on Tuesday 10th March 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Genetic Technologies

Price: 0.005 AUD

ASX:GTG
Market: ASX
Market Cap: $15.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Viva Gold kicking off PEA of Tonopah gold project in Nevada

Viva Gold Corp (CVE:VAU) (OTCBB: VAUCF) CEO James Hesketh tells Proactive the Nevada-based gold exploration and development company will begin its Preliminary Economic Assessment of its Tonopah gold project. Hesketh says that based on positive preliminary metallurgical results from its fall...

13 hours, 9 minutes ago

2 min read